# Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: A Biotech Gem with 77% Upside Potential

- Link: https://www.directorstalkinterviews.com/mineralys-therapeutics-inc-mlys-stock-analysis-a-biotech-gem-with-77-upside-potential/4121241437
- Published: 2026-02-24T11:31:00+00:00
- Author: Madison Wilson

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is capturing the attention of investors
with its compelling potential for growth in the biotechnology sector. With a market
capitalization of $2.29 billion, this clinical-stage biopharmaceutical company is
positioning itself as a key player in the treatment of diseases driven by dysregulated
aldosterone, such as hypertension and chronic kidney disease.

The current trading price of $28.93 reflects a modest recent increase, yet the stock
sits comfortably within its 52-week range of $8.76 to $47.33. This positions it 
well for potential upside, especially considering the average analyst target price
of $51.29, which suggests a robust potential gain of 77.28%.

Mineralys Therapeutics is spearheading its clinical development with lorundrostat,
an innovative, orally administered, highly selective aldosterone synthase inhibitor.
This drug is designed to tackle cardiorenal conditions linked to dysregulated aldosterone,
offering a novel approach to treating conditions like hypertension and chronic kidney
disease. The company has initiated a Phase 2 trial for lorundrostat and is advancing
with a pivotal clinical program aimed at treating uncontrolled or resistant hypertension.

Despite the promising clinical pipeline, Mineralys presents some financial challenges
typical for companies at this stage. The absence of a P/E ratio and negative EPS
of -2.92 highlight the current lack of profitability, with a return on equity standing
at -42.14%. Furthermore, the company’s free cash flow is negative, underscoring 
the need for continued investment as it progresses through clinical trials.

Analysts are optimistic about Mineralys’ prospects, with eight buy ratings and only
one hold rating, underscoring strong confidence in the company’s future. The target
price range of $42.00 to $56.00 reflects this bullish sentiment, coupled with the
potential for substantial returns.

From a technical perspective, the stock’s 50-day moving average is at $33.08, indicating
a recent pullback but still showing strength above the 200-day moving average of
$28.06. The RSI (14) stands at 71.26, entering the overbought territory, which could
signal a short-term correction, though the longer-term outlook remains positive 
given the MACD and signal line dynamics.

Investors should also consider the strategic implications of Mineralys’ focus on
aldosterone-related therapies. As the prevalence of hypertension and chronic kidney
disease continues to rise, the demand for effective treatments grows, potentially
driving significant future revenue streams for the company.

While Mineralys does not currently offer dividends, its zero payout ratio is typical
for a biotech firm in the clinical stage, where reinvestment into research and development
takes precedence over shareholder returns. This reinvestment strategy is crucial
for advancing their product pipeline and achieving long-term growth.

For investors looking to capture potential growth in the biotech sector, Mineralys
Therapeutics provides a compelling opportunity. With a promising drug candidate,
strong analyst support, and significant upside potential, MLYS is a stock to watch
closely as it advances through clinical trials and moves closer to commercialization.

Share on: